ICU Medical (NASDAQ:ICUI) Stock Breaks Above 200-Day Moving Average - Should You Sell?

Key Points

• ICU Medical shares broke above their 200-day moving average, trading as high as $166.71 and last changing hands at $164.03.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $192.80, although some firms recently downgraded the stock to “Hold” or “Market Perform.”
• The company beat quarterly earnings and revenue expectations, but insiders sold $3.9 million of stock over the past three months, while the shares trade at a high forward valuation.

ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $146.40 and traded as high as $166.71. ICU Medical shares last traded at $164.03, with a volume of 290,623 shares traded.

Analysts Set New Price Targets

ICUI has been the subject of several analyst reports. Needham & Company LLC boosted their target price on shares of ICU Medical from $165.00 to $187.00 and gave the company a "buy" rating in a research note on Friday, August 7th. Zacks Research lowered shares of ICU Medical from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 28th. KeyCorp lifted their price objective on shares of ICU Medical from $164.00 to $182.00 and gave the company an "overweight" rating in a report on Tuesday, July 21st. Piper Sandler lifted their price objective on shares of ICU Medical from $163.00 to $195.00 and gave the company an "overweight" rating in a report on Friday, August 7th. Finally, Sanford C. Bernstein downgraded shares of ICU Medical to a "market perform" rating in a research report on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $192.80.

ICU Medical Price Performance

The firm has a market capitalization of $4.10 billion, a PE ratio of 139.01, a PEG ratio of 2.08 and a beta of 0.75. The stock has a 50-day moving average price of $168.87 and a 200 day moving average price of $146.40. The company has a quick ratio of 1.21, a current ratio of 2.43 and a debt-to-equity ratio of 0.56.

ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.46. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%.The business had revenue of $547.88 million during the quarter, compared to the consensus estimate of $533.44 million. During the same period in the prior year, the company posted $2.10 EPS. The business's quarterly revenue was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Equities analysts forecast that ICU Medical, Inc. will post 7.22 EPS for the current fiscal year.

Insider Activity at ICU Medical

In other ICU Medical news, insider Ben Sousa sold 2,250 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $178.32, for a total transaction of $401,220.00. Following the transaction, the insider directly owned 3,076 shares of the company's stock, valued at $548,512.32. This trade represents a 42.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Daniel Woolson sold 5,417 shares of the stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $181.33, for a total transaction of $982,264.61. Following the transaction, the vice president directly owned 17,062 shares in the company, valued at approximately $3,093,852.46. The trade was a 24.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 21,830 shares of company stock valued at $3,905,003 in the last three months. Company insiders own 2.10% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ICUI. Squarepoint Ops LLC acquired a new position in shares of ICU Medical during the second quarter valued at approximately $3,744,000. Allworth Financial LP boosted its stake in shares of ICU Medical by 155.1% in the second quarter. Allworth Financial LP now owns 176 shares of the medical instruments supplier's stock worth $26,000 after acquiring an additional 107 shares during the last quarter. Arizona State Retirement System boosted its stake in shares of ICU Medical by 1.7% in the second quarter. Arizona State Retirement System now owns 6,551 shares of the medical instruments supplier's stock worth $960,000 after acquiring an additional 109 shares during the last quarter. Nykredit A S purchased a new stake in shares of ICU Medical during the second quarter worth approximately $135,000. Finally, Amundi increased its position in shares of ICU Medical by 31.5% during the second quarter. Amundi now owns 8,512 shares of the medical instruments supplier's stock worth $1,248,000 after purchasing an additional 2,037 shares in the last quarter. 96.10% of the stock is owned by hedge funds and other institutional investors.

About ICU Medical

ICU Medical, Inc develops, manufactures and sells medical devices used in infusion therapy, critical care and oncology. Its product portfolio includes infusion pumps, IV administration sets, needle-free connectors, vascular access devices, patient monitoring equipment and related accessories designed to support the delivery of fluids and medications and the monitoring of patients in healthcare settings.

The company also provides products for the safe handling of hazardous drugs, including closed-system transfer devices used in oncology and pharmacy operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.